Rizatriptan
Maxalt, Maxalt-mlt, Rizafilm, Rizatriptan Benzoate (rizatriptan) is a small molecule pharmaceutical. Rizatriptan was first approved as Maxalt-mlt on 1998-06-29. It is used to treat migraine disorders in the USA. The pharmaceutical is active against 5-hydroxytryptamine receptor 1D and 5-hydroxytryptamine receptor 1B. In addition, it is known to target 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 1E, and 5-hydroxytryptamine receptor 1F.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
Trade Name
FDA
EMA
Maxalt, Maxalt-mlt, Rizafilm (generic drugs available since 2012-12-31)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| rizatriptan benzoate | ANDA | 2023-08-08 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| migraine disorders | EFO_0003821 | D008881 | G43 |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Rizatriptan Benzoate, Rizafilm, Gensco | |||
| 9301948 | 2034-07-30 | DS, DP | |
HCPCS
No data
Clinical
Clinical Trials
41 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Migraine disorders | D008881 | EFO_0003821 | G43 | 1 | 1 | 20 | 7 | 5 | 34 |
| Epilepsy | D004827 | EFO_0000474 | G40.9 | — | — | 1 | 1 | — | 2 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | — | 1 | — | 1 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | — | — | 1 | — | 1 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | — | — | 1 | — | 1 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | — | — | 1 | — | 1 |
| Restless legs syndrome | D012148 | EFO_0004270 | G25.81 | — | — | — | 1 | — | 1 |
| Cognitive dysfunction | D060825 | HP_0001268 | G31.84 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Migraine without aura | D020326 | EFO_0005296 | G43.0 | — | — | 1 | — | — | 1 |
| Migraine with aura | D020325 | EFO_0005295 | G43.1 | — | — | 1 | — | — | 1 |
| Vertigo | D014717 | — | H81.39 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Post-traumatic headache | D051298 | — | G44.3 | — | — | — | — | 1 | 1 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | — | — | — | — | 1 | 1 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Rizatriptan |
| INN | rizatriptan |
| Description | Rizatriptan is a member of tryptamines. It has a role as a serotonergic agonist, a vasoconstrictor agent and an anti-inflammatory drug. It is functionally related to a N,N-dimethyltryptamine. |
| Classification | Small molecule |
| Drug class | antimigraine agents (5-HT1 receptor agonists); sumatriptan derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12 |
Identifiers
| PDB | — |
| CAS-ID | 144034-80-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL905 |
| ChEBI ID | 48273 |
| PubChem CID | 5078 |
| DrugBank | DB00953 |
| UNII ID | 51086HBW8G (ChemIDplus, GSRS) |
Target
Agency Approved
HTR1D
HTR1D
HTR1B
HTR1B
Organism
Homo sapiens
Gene name
HTR1D
Gene synonyms
HTR1DA, HTRL
NCBI Gene ID
Protein name
5-hydroxytryptamine receptor 1D
Protein synonyms
5-HT-1D, 5-HT-1D-alpha, 5-hydroxytryptamine (serotonin) receptor 1D, G protein-coupled, Serotonin 1D alpha receptor, Serotonin receptor 1D
Uniprot ID
Mouse ortholog
Htr1d (15552)
5-hydroxytryptamine receptor 1D (Q8BUW7)
Alternate
HTR1A
HTR1A
HTR1E
HTR1E
HTR1F
HTR1F
Organism
Homo sapiens
Gene name
HTR1A
Gene synonyms
ADRB2RL1, ADRBRL1
NCBI Gene ID
Protein name
5-hydroxytryptamine receptor 1A
Protein synonyms
5-HT1a receptor, 5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled, G-21, guanine nucleotide-binding regulatory protein-coupled receptor, Serotonin receptor 1A
Uniprot ID
Mouse ortholog
Htr1a (15550)
5-hydroxytryptamine receptor 1A (Q8BGS4)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Rizatriptan
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,376 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,485 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use